Krazati (adagrasib tablets - Mirati Therapeutics) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient has unresectable, advanced, or metastatic disease
• Patient has KRAS G12C mutation-positive disease
• Patient meets ONE of the following (i or ii): i) The medication is prescribed as part of a combination regimen for colon or rectal cancer; OR ii) As per the prescriber, the patient is unable to tolerate combination therapy
• Patient has previously received a chemotherapy regimen for colon or rectal cancer

Approval duration

1 year